Lipid disorders in type 2 diabetes.
Laakso
Markku
M
Department of Medicine, University of Kuopio, Kuopio, Finland. markku.laakso@kuh.fi
D050197:Atherosclerosis / Q000097:blood / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D050171:Dyslipidemias / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D011345:Fenofibrate / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D015228:Hypertriglyceridemia / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D015337:Multicenter Studies as Topic; D012307:Risk Factors; D006113:United Kingdom / Q000453:epidemiology
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011345:Fenofibrate